Dr. Suzy Melkonian, MD

Dr. Melkonian practices at Los Angeles Cancer Network in Vannuys, California.

Dr. Melkonian's NPI, 1730188152, was assigned on July 18, 2005. Dr. Melkonian graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 1994. Dr. Melkonian holds California license G83152.

Dr. Melkonian's primary practice is Los Angeles Cancer Network, at 6850 N Sepulveda Blvd, Vannuys, CA 91405 in Los Angeles County. The practice phone is (213) 977-1214.

Dr. Melkonian's primary practice is Los Angeles Cancer Network in Vannuys, California. Dr. Melkonian is also affiliated with Providence Holy Cross Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Melkonian to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melkonian practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Melkonian's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Melkonian is board certified in medical oncology by the American Board of Internal Medicine. Dr. Melkonian is licensed in California.

Dmand AI lists breast cancer, chronic anemia, immune deficiency disease and lymphoma among the conditions Dr. Melkonian treats.

CMS data shows 1,181 Medicare services from Dr. Melkonian across 12 procedure codes in 2024, for 50 Medicare patients. Medicare paid $16,742 for them. Every service was in an office.

CMS counts 50 Medicare patients who saw Dr. Melkonian in 2024. The largest group is 75 to 84, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 58% are also on Medicaid. Their average risk score is 2.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Melkonian's median patient age at 63, with 62% women.

In 2024, Dr. Melkonian wrote 486 Medicare Part D claims for 78 patients. 34% of them were for generic drugs. CMS names the drug for 299 of them, across 7 drugs with 11 or more claims each, at $1,070,021 in total drug cost. In 2023, CMS named 436 claims across 18 drugs.

Dr. Melkonian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Melkonian as offering telehealth.

Dmand AI links Dr. Melkonian to 5 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Rectal Neoplasms and Triple Negative Breast Neoplasms. City of Hope Medical Center sponsors the most, 5.

CMS Open Payments shows 1,050 general payments to Dr. Melkonian from 76 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 79% of the total. ARIAD Pharmaceuticals, Inc. paid the most, $3,414.

Dr. Melkonian graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 1994. Dr. Melkonian is a member of ASCO.

Dr. Melkonian is in network with 16 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.